Let this progress guide us toward even better results and provide everyone, regardless of age and gender, with better diabetes control.
One of the significant advantages of the Medtronic Minimed 780G system is its ability to adapt to hormonal changes in women, especially during the menstrual cycle. Hormonal fluctuations during menstruation can affect glucose levels, presenting a challenge in managing diabetes. This system helps women maintain stable glucose control by adjusting insulin delivery in line with changes in the body.
At a scientific symposium during the ATTD conference, data from Prof. Yasmine Elhenawy from Egypt was presented. The study followed 15 girls aged 14 to 21, and the results showed that the Minimed 780G system enabled achieving Time in Range values higher than the internationally recommended 70% throughout the entire menstrual cycle.
A slide from one of the many Medtronic symposia at ATTD2025
Pre-pregnancy Diabetes and 780G
Additionally, the closed-loop system is also useful for women with pre-gestational diabetes, i.e., those who had diabetes before pregnancy. Maintaining optimal glucose levels before and during pregnancy is crucial for the health of both the mother and the child. The automated features of this system can significantly help reduce risks associated with uncontrolled glucose levels during this sensitive period.
By using technologies like the Minimed 780G system, women with diabetes can more easily overcome the unique challenges they face, which ultimately may help reduce the gender disparities in diabetes care.
Pregnant Women and the Lancet Study
A recent study published in the prestigious journal Lancet Diabetes & Endocrinology explored the effectiveness of advanced hybrid closed-loop therapy compared to standard insulin therapy in pregnant women with type 1 diabetes. The study, known as CRISTAL, involved pregnant women with type 1 diabetes to assess the impact of the closed-loop system on glucose control during pregnancy.
Excellent diabetes control in three girls from Croatia during the conference, thanks to Medtronic insulin pumps
The results showed that the use of the closed-loop system led to significant improvement in glucose control, reducing time spent in hyperglycemia and increasing time within the target glucose range. The findings suggest that this therapy can provide better glycemic control for pregnant women with type 1 diabetes compared to standard insulin therapy.
However, the authors emphasize the need for further research to confirm the safety and effectiveness of closed-loop systems throughout pregnancy and fully understand their potential impact on outcomes for both mother and child.
In the next couple of years, it is expected that the first Libre sensors will become compatible with Medtronic insulin pumps, which represents an important step towards even greater accessibility and flexibility in diabetes management!
Ohad Cohen, Medtronic Global Senior Director, Medical Affairs
Minimed 780G and Children
Currently, this insulin pump is approved for children aged 7 and older. We are excited to share information from Amsterdam: Medtronic is working intensively on expanding access to the technology for even younger age groups, starting from 2 years old! 😊
